Canadian Association of Gastroenterology Clinical Practice Guidelines: The Use of Tumour Necrosis Factor-Alpha Antagonist Therapy in Crohn’s Disease

Canadian Association of Gastroenterology Clinical Practice Guidelines: The Use of Tumour Necrosis Factor-Alpha Antagonist Therapy in Crohn’s Disease

BACKGROUND: Guidelines regarding the use of infliximab in Crohn’s disease were previously published by the Canadian Association of Gastroenterology in 2004. However, recent clinical findings and drug developments warrant a review and update of these guidelines.

Saved in:
Bibliographic Details
Main Authors: Daniel C Sadowski, Charles N Bernstein, Alain Bitton, Ken Croitoru, Richard N Fedorak, Anne Griffiths, the CAG Crohn’s Consensus Group
Format: Article
Language:English
Published: Wiley 2009-01-01
Series:Canadian Journal of Gastroenterology
Online Access:http://dx.doi.org/10.1155/2009/201430
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BACKGROUND: Guidelines regarding the use of infliximab in Crohn’s disease were previously published by the Canadian Association of Gastroenterology in 2004. However, recent clinical findings and drug developments warrant a review and update of these guidelines.
ISSN:0835-7900

Similar Items